DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0280759 A1 MAHR Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0280759 A1 MAHR Et Al US 20160280759A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0280759 A1 MAHR et al. (43) Pub. Date: Sep. 29, 2016 (54) NOVEL PEPTIDES AND COMBINATION OF Publication Classification PEPTDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMIORS (51) Int. Cl. C07K I4/74 (2006.01) (71) Applicant: immatics biotechnologies GmbH, C07K 6/28 (2006.01) Tuebingen (DE) C07K 14/725 (2006.01) CI2O I/68 (2006.01) (72) Inventors: Andrea MAHR, Tuebingen (DE); Toni A6139/00 (2006.01) WEINSCHENK, Aichwald (DE); (52) U.S. Cl. Oliver SCHOOR, Tuebingen (DE): CPC ....... C07K 14/70539 (2013.01); C12O 1/6886 Jens FRITSCHE, Dusslingen (DE): (2013.01); A61K 39/00II (2013.01); C07K Harpreet SINGH, Muenchen (DE): 14/7051 (2013.01); C07K 16/2833 (2013.01); Lea STEVERMANN, Tuebingen (DE) CI2O 2600/106 (2013.01); C12O 2600/158 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/34 (2013.01) Assignee: immatics biotechnologies GmbH (73) (57) ABSTRACT The present invention relates to peptides, proteins, nucleic (21) Appl. No.: 15/083,075 acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immuno (22) Filed: Mar. 28, 2016 therapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can Related U.S. Application Data for example serve as active pharmaceutical ingredients of (60) Provisional application No. 62/139,189, filed on Mar. vaccine compositions that stimulate anti-tumor immune 27, 2015. responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histo (30) Foreign Application Priority Data compatibility complex (MHC), or peptides as Such, can also be targets of antibodies, soluble T-cell receptors, and other Mar. 27, 2015 (GB) ................................... 1505.305.1 binding molecules. Patent Application Publication Sep. 29, 2016 Sheet 1 of 65 US 2016/0280759 A1 aqeene 30, sun Aleic Wuoleuesad enee Patent Application Publication Sep. 29, 2016 Sheet 2 of 65 US 2016/0280759 A1 eqeeAe Ou Sun Aescu Wuoleuesed enee Patent Application Publication Sep. 29, 2016 Sheet 3 of 65 US 2016/0280759 A1 uopueyau??||90sænss? A ency uoleuased eA3ee Patent Application Publication Sep. 29, 2016 Sheet 4 of 65 US 2016/0280759 A1 eqegeAe Ou aggeeNe 3Ou eqeeAe Ou uapueySau??||90sænss? (10:Z0),V)THINGGIHTRI:òp?død-CII?àn?? Sufi Auerq Wuoleuesed enee Patent Application Publication Sep. 29, 2016 Sheet 5 of 65 US 2016/0280759 A1 egee Aeou eqeeAeo eqeeAeo "IT-----ru;-)eqeeAeou------------------•~~~------mw==!'»•-------,} eqeeA8 (IO:ZO?V)ISAIBXETAS:?p?dad eqeeAe Ou ETaun3}+ Z:C||OES Sun Aueuqwuoeuesed enee Patent Application Publication Sep. 29, 2016 Sheet 6 of 65 US 2016/0280759 A1 anss?uapueo Sun Auerq Wuoleueseid eAgee Patent Application Publication Sep. 29, 2016 Sheet 7 of 65 US 2016/0280759 A1 | anss?uopueo ?T?un314 Sun Muecy toleueSeid enee Patent Application Publication Sep. 29, 2016 Sheet 8 of 65 US 2016/0280759 A1 ***** eqegene Ou eqeene OU Sun Aueniquwuogeauasad enee Patent Application Publication Sep. 29, 2016 Sheet 9 of 65 US 2016/0280759 A1 | eqelehe ot --r--r--r--r---------Tm Sun Aequw uopeiussaid eNee Patent Application Publication Sep. 29, 2016 Sheet 10 of 65 US 2016/0280759 A1 Sun AeqWuoleuese densee Patent Application Publication Sep. 29, 2016 Sheet 11 of 65 US 2016/0280759 A1 : 3 uoisseudx enee Patent Application Publication Sep. 29, 2016 Sheet 12 of 65 US 2016/0280759 A1 & uoissed){ enee Patent Application Publication Sep. 29, 2016 Sheet 13 of 65 US 2016/0280759 A1 tossedX 8Agee Patent Application Publication Sep. 29, 2016 Sheet 14 of 65 US 2016/0280759 A1 & saqduuesuaouedBun||89 anee Patent Application Publication Sep. 29, 2016 Sheet 15 of 65 US 2016/0280759 A1 enee Patent Application Publication Sep. 29, 2016 Sheet 16 of 65 US 2016/0280759 A1 ld LWOSMWXI dinos duosuen Wid: enee Patent Application Publication Sep. 29, 2016 Sheet 17 of 65 US 2016/0280759 A1 Wido-A dnous dioSue WXld eMee Patent Application Publication Sep. 29, 2016 Sheet 18 of 65 US 2016/0280759 A1 ALEdNA dnouildliosue 12 NXidewele&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&& Patent Application Publication Sep. 29, 2016 Sheet 20 of 65 US 2016/0280759 A1 8 Patent Application Publication Sep. 29, 2016 Sheet 21 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 22 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 23 of 65 US 2016/0280759 A1 www.wywww.wyww. s Patent Application Publication Sep. 29, 2016 Sheet 24 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 25 of 65 US 2016/0280759 A1 s s Patent Application Publication Sep. 29, 2016 Sheet 26 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 27 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 28 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 29 of 65 US 2016/0280759 A1 *..4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 (~~*----·*...::::: Patent Application Publication Sep. 29, 2016 Sheet 30 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 31 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 32 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 33 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 34 of 65 US 2016/0280759 A1 {$ $ $ $ $ $ $ $ $ $ $ $ $ $ { Patent Application Publication Sep. 29, 2016 Sheet 35 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 36 of 65 US 2016/0280759 A1 s Patent Application Publication Sep. 29, 2016 Sheet 37 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 38 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 39 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 40 of 65 US 2016/0280759 A1 s sy Patent Application Publication Sep. 29, 2016 Sheet 41 of 65 US 2016/0280759 A1 & Patent Application Publication Sep. 29, 2016 Sheet 42 of 65 US 2016/0280759 A1 **** Patent Application Publication Sep. 29, 2016 Sheet 43 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 44 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 45 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 46 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 47 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 48 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 49 of 65 US 2016/0280759 A1 : 33 8. Patent Application Publication Sep. 29, 2016 Sheet 50 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 51 of 65 US 2016/0280759 A1 88 Patent Application Publication Sep. 29, 2016 Sheet 52 of 65 US 2016/0280759 A1 ????????????? Patent Application Publication Sep. 29, 2016 Sheet 53 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 54 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 55 of 65 US 2016/0280759 A1 Patent Application Publication Sep. 29, 2016 Sheet 56 of 65 US 2016/0280759 A1 Figure 6 A Stimulationr Stimulation ta HLA-A*02/SeqD No 11 HLA-A*02inegative ctrl o er (O S. Sp N w > BV650. A*02iSeq D. No 11 B Stirulation Stimulation st HLA-A*02/SeqiD No 14 HLA-A*02/negative ctrl s c f r o N rf o APC: A*02/SeqD No 14 Patent Application Publication Sep. 29, 2016 Sheet 57 of 65 US 2016/0280759 A1 Figure 6 (continued) C Stimulation Stimulation HLA-A*02/Seq D. No 157 HA-A*02inegative ctrl 2 mir-5 mr.0.00% C3 f S Sp < o 8 > PE-Cy7: A*02/Seq D No. 157 D c Stimulation Stinuation & HLA-A*02fSeq D. No 233 HLA-A*02inegative ctrl --- ------ s f N Sp t c 8 PE A*02/Seq D. No 233 Patent Application Publication Sep. 29, 2016 Sheet 58 of 65 US 2016/0280759 A1 Figure 6 (continued) E Stinuation Stimulation HLA-A*02iSeq D. No 85 HLA-A*02/negative ctrl PE: A*02iSeq D. No 85 Stinuation Stimulation HA-A*02iSeq D No. 89 HLA-A*02inegative ctrl oC) i 1.10% 8 O 2 e s CO R Sp c3 PE-Cy7: A*02iSeq D. No 89 Patent Application Publication Sep. 29, 2016 Sheet 59 of 65 US 2016/0280759 A1 Figure 6 (continued) Stimulation Stinuation to HLA-A*02iSeq D. No 55 HLA-A*02/negative ctrl o 2. f & So (3. d 8 C. PE: A*02iSeq D. No 155 y Stimulation Stimulation HLA-A*02/Seqld No. 153 C : 2. p & d s PE: A*02iSeq D. No 153 Patent Application Publication Sep. 29, 2016 Sheet 60 of 65 US 2016/0280759 A1 Figure 6 (continued) Stinuation Stimulation HLA-A*02iSeq D. No 264 HLA-A*02/negative ctrl s Cs 2 C s Of & k c c D PE-Cy7: A*02/SeqID No. 264 Stinuation Stimulation HLA-A*02iSeq D. No 117 HLA-A*02/negative ctrl APC: A*02/Seq D. No 117 Patent Application Publication Sep. 29, 2016 Sheet 61 of 65 US 2016/0280759 A1 Figure 6 (continued) Stimulation Stimulation HLA-A*02/SeqD No. 253 HLA-A*02/negative ctrl 0.00% a-------------------------------------------------------------- APC: A*02iSeq D No.
Load more

Recommended publications
  • Cancer-Testis Antigens MAGEA Proteins Are Incorporated Into Extracellular Vesicles Released by Cells
    www.oncotarget.com Oncotarget, 2019, Vol. 10, (No. 38), pp: 3694-3708 Research Paper Cancer-testis antigens MAGEA proteins are incorporated into extracellular vesicles released by cells Anneli Kuldkepp1, Magda Karakai1, Eve Toomsoo1, Olavi Reinsalu1 and Reet Kurg1 1Institute of Technology, University of Tartu, Tartu, Estonia Correspondence to: Reet Kurg, email: [email protected] Keywords: cancer-testis antigens; MAGEA; extracellular vesicles; microvesicles Received: December 13, 2018 Accepted: May 13, 2019 Published: June 04, 2019 Copyright: Kuldkepp et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Melanoma-associated antigen A (MAGEA) family proteins represent a class of tumor antigens that are expressed in a variety of malignant tumors, but their expression in normal tissues is restricted to germ cells. MAGEA family consists of eleven proteins that are highly conserved sharing the common MAGE homology domain (MHD). In the current study, we show that MAGEA4 and MAGEA10 proteins are incorporated into extracellular vesicles released by mouse fibroblast and human osteosarcoma U2OS cells and are expressed, at least partly, on the surface of released EVs. The C-terminal part of the protein containing MHD domain is required for this activity. Expression of MAGEA proteins induced the budding of cells and formation of extracellular vesicles with 150 to 1500 nm in diameter. Our data suggest that the release of MAGEA-positive EVs is at least to some extent induced by the expression of MAGEA proteins itself.
    [Show full text]
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) Beyond SMARCA4 Mutations: a Comprehensive Genomic Analysis
    cells Article Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis Aurélie Auguste 1,Félix Blanc-Durand 2 , Marc Deloger 3 , Audrey Le Formal 1, Rohan Bareja 4,5, David C. Wilkes 4 , Catherine Richon 6,Béatrice Brunn 2, Olivier Caron 6, Mojgan Devouassoux-Shisheboran 7,Sébastien Gouy 2, Philippe Morice 2, Enrica Bentivegna 2, Andrea Sboner 4,5,8, Olivier Elemento 4,8, Mark A. Rubin 9 , Patricia Pautier 2, Catherine Genestie 10, Joanna Cyrta 4,9,11 and Alexandra Leary 1,2,* 1 Medical Oncologist, Gynecology Unit, Lead Translational Research Team, INSERM U981, Gustave Roussy, 94805 Villejuif, France; [email protected] (A.A.); [email protected] (A.L.F.) 2 Gynecological Unit, Department of Medicine, Gustave Roussy, 94805 Villejuif, France; [email protected] (F.B.-D.); [email protected] (B.B.); [email protected] (S.G.); [email protected] (P.M.); [email protected] (E.B.); [email protected] (P.P.) 3 Bioinformatics Core Facility, Gustave Roussy Cancer Center, UMS CNRS 3655/INSERM 23 AMMICA, 94805 Villejuif, France; [email protected] 4 Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10001, USA; [email protected] (R.B.); [email protected] (D.C.W.); [email protected] (A.S.); [email protected] (O.E.); [email protected] (J.C.) 5 Institute for Computational Biomedicine, Weill Cornell
    [Show full text]
  • Seromic Profiling of Ovarian and Pancreatic Cancer
    Seromic profiling of ovarian and pancreatic cancer Sacha Gnjatica,1, Erika Rittera, Markus W. Büchlerb, Nathalia A. Gieseb, Benedikt Brorsc, Claudia Freid, Anne Murraya, Niels Halamad, Inka Zörnigd, Yao-Tseng Chene, Christopher Andrewsf, Gerd Rittera, Lloyd J. Olda,1, Kunle Odunsig,2, and Dirk Jägerd,2 aLudwig Institute for Cancer Research Ltd, Memorial-Sloan Kettering Cancer Center, New York, NY 10065; bDepartment of General Surgery, cDepartment of Theoretical Bioinformatics, and dMedizinische Onkologie, Nationales Centrum für Tumorerkrankungen, University Hospital Heidelberg, Heidelberg D-69120, Germany; eDepartment of Pathology, Weill Medical College of Cornell University, New York, NY 10065; and fDepartment of Biostatistics and gDepartment of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263 Contributed by Lloyd J. Old, December 10, 2009 (sent for review August 20, 2009) Autoantibodies, a hallmark of both autoimmunity and cancer, analyzing a series of lung cancer and healthy control sera on a represent an easily accessible surrogate for measuring adaptive small array (329 proteins) for antigen reactivity using this anti- immune responses to cancer. Sera can now be assayed for re- body profiling method, referred to here as “seromics,” we were activity against thousands of proteins using microarrays, but there able to detect known antigens with sensitivity and specificity is no agreed-upon standard to analyze results. We developed a set comparable to ELISA, as well as new antigens that are now of tailored quality control and normalization procedures based on under further investigation. Contrary to gene microarrays where ELISA validation to allow patient comparisons and determination changes in the pattern of gene expression are detected in clus- of individual cutoffs for specificity and sensitivity.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,662,561 B2 Godfrey Et Al
    USOO7662561 B2 (12) United States Patent (10) Patent No.: US 7,662,561 B2 Godfrey et al. (45) Date of Patent: Feb. 16, 2010 (54) IDENTIFICATION OF MARKERS IN 6,440,725 B1 8/2002 Pourahmadi et al. ESOPHAGEAL CANCER, COLON CANCER, 7,101,663 B2 9/2006 Godfrey et al. HEAD AND NECK CANCER, AND 2001/005.1344 A1* 12/2001 Shalon et al. .................. 435/6 MELANOMA 2006/0068418 A1* 3/2006 Godfrey et al. ................ 435/6 (75) Inventors: Tony E. Godfrey, Bronxville, NY (US); FOREIGN PATENT DOCUMENTS Liqiang Xi, Plainsboro, NJ (US); Siva EP 105O587 11, 2000 Raja, Jamaica Plain, MA (US); Steven WO WO95/11687 5, 1995 J. Hughes, Blawnox, PA (US); William WO WO98,0897O 3, 1998 E. Gooding, Pittsburgh, PA (US) WO WO99, 13104 3, 1999 WO WOOOf 44774 8, 2000 (73) Assignee: University of Pittsburgh-Of the WO WOOOf 72970 12/2000 commonwealth System of Higher WO WOOOf73412 12/2000 WO WOOOf73413 12/2000 Education, Pittsburgh, PA (US) WO WOO1/O1129 1, 2001 WO WOO1? 45845 6, 2001 (*) Notice: Subject to any disclaimer, the term of this WO WO O1, 57253 8, 2001 patent is extended or adjusted under 35 WO WOO1 (84.463 11, 2001 U.S.C. 154(b) by 159 days. WO WO O2, 18902 3, 2002 WO WO O2/O52030 T 2002 (21) Appl. No.: 11/178,134 WO WO O2/O70751 9, 2002 WO WOO3/O55973 T 2003 (22) Filed: Jul. 8, 2005 WO WOO3,O72253 9, 2003 WO WOO3,O77O55 9, 2003 (65) Prior Publication Data WO WO 2004/048931 6, 2004 US 2006/OO1929.0 A1 Jan.
    [Show full text]
  • Frequent MAGE Mutations in Human Melanoma
    Frequent MAGE Mutations in Human Melanoma Otavia L. Caballero1*.¤, Qi Zhao2., Donata Rimoldi3, Brian J. Stevenson3, Suzanne Svobodova´ 4, Sylvie Devalle1, Ute F. Ro¨ hrig3, Anna Pagotto5, Olivier Michielin3, Daniel Speiser3, Jedd D. Wolchok1,6, Cailian Liu6, Tanja Pejovic7, Kunle Odunsi8, Francis Brasseur9, Benoit J. Van den Eynde9, Lloyd J. Old1, Xin Lu5, Jonathan Cebon4, Robert L. Strausberg10, Andrew J. Simpson10 1 Ludwig Institute for Cancer Research Ltd, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, 2 J. Craig Venter Institute, Rockville, Maryland, United States of America, 3 Ludwig Institute for Cancer Research Ltd, Lausanne Branch, Lausanne, Switzerland, 4 Ludwig Institute for Cancer Research Ltd, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australia, 5 Nuffield Department of Clinical Medicine, University of Oxford, Ludwig Institute for Cancer Research Ltd, Oxford Branch, Headington, Oxford, United Kingdom, 6 Department of Medicine and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, 7 Division of Gynecologic Oncology and the Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America, 8 Department of Gynecological Oncology and Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York, United States of America, 9 Ludwig Institute for Cancer Research Ltd, Brussels Branch, Universite´ catholique de Louvain, Brussels, Belgium, 10 Ludwig Institute for Cancer Research Ltd, New York, New York, United States of America Abstract Background: Cancer/testis (CT) genes are expressed only in the germ line and certain tumors and are most frequently located on the X-chromosome (the CT-X genes).
    [Show full text]
  • Genome-Wide Expression Profiling Reveals New Insights Into Pathogenesis and Progression of Testicular Germ Cell Tumors
    CANCER GENOMICS & PROTEOMICS 4: 359-368 (2007) Genome-wide Expression Profiling Reveals New Insights into Pathogenesis and Progression of Testicular Germ Cell Tumors KATHARINA BIERMANN1*, LUKAS CARL HEUKAMP1*, KLAUS STEGER2, HUI ZHOU1, FOLKER ERNST FRANKE3, VIOLETTA SONNACK2, RALPH BREHM4, JOHANNES BERG5, PATRICK JAN BASTIAN6, STEFAN CAJETAN MÜLLER6, LIHUA WANG-ECKERT7 and REINHARD BUETTNER1 1Department of Pathology and 6Department of Urology, University of Bonn; 2Department of Urology and Pediatric Urology; 3Department of Pathology, and 4Institute of Veterinary-Anatomy, -Histology and -Embryology, University of Giessen; 5Institute of Theoretical Physics, University of Cologne; 7Laboratory for Experimental Psychiatry, Life & Brain Center, Bonn, Germany Abstract. Testicular germ cell tumors (GCT) are the most genetic pathways driving the transition to seminomas and frequent malignancy in young adults and arise from embryonal carcinomas from their respective precursor lesions. intratubular germ cell neoplasia undetermined (IGCNU, also referred to as carcinoma in situ, CIS). To determine the The incidence of testicular germ cell tumors (GCT) is transcriptional programs involved in the transition from steadily increasing all over the world (6-11 per 100,000) (1, normal germ cells to GCT, and to further elucidate genetic 2). In general, GCT is suggested to be a part of the testicular differences between seminomas and non-seminomatous GCT dysgenesis syndrome, which includes cryptorchidism and the global expression profile of 12 neoplastic and 3 normal testicular atrophy (3). First described by Skakkebaek in 1972, testicular tissues were investigated by whole genome cDNA intratubular germ cell neoplasia undetermined, also referred microarrays. Transcriptional differences between seminomas to as carcinoma in situ or testicular intratubular neoplasia and embryonal carcinomas were determined and gene (IGCNU, CIS, TIN) is the common precursor lesion of all signatures characterizing histological subtypes of GCT were GCT except spermatocytic seminoma (4, 5).
    [Show full text]
  • A Multi-Scale Structural Interactome Browser for Genomic Studies
    bioRxiv preprint doi: https://doi.org/10.1101/126862; this version posted April 12, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Interactome INSIDER: a multi-scale structural interactome browser for genomic studies Michael J. Meyer1,2,3,†, Juan Felipe Beltrán1,2,†, Siqi Liang1,2,†, Robert Fragoza2,4, Aaron Rumack1,2, Jin Liang2, Xiaomu Wei2,5, and Haiyuan Yu1,2,* 1Department of Biological Statistics and Computational Biology, Cornell University, Ithaca, New York, 14853, USA 2Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, New York, 14853, USA 3Tri-Institutional Training Program in Computational Biology and Medicine, New York, New York, 10065, USA 4Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY 14853, USA. 5Department of Medicine, Weill Cornell College of Medicine, New York, New York, 10065, USA. †The authors wish it to be known that, in their opinion, the first 3 authors should be regarded as joint First Authors. *To whom correspondence should be addressed. Tel: 607-255-0259; Fax: 607-255-5961; Email: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/126862; this version posted April 12, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
    [Show full text]
  • Genomic and Expression Profiling of Human Spermatocytic Seminomas: Primary Spermatocyte As Tumorigenic Precursor and DMRT1 As Candidate Chromosome 9 Gene
    Research Article Genomic and Expression Profiling of Human Spermatocytic Seminomas: Primary Spermatocyte as Tumorigenic Precursor and DMRT1 as Candidate Chromosome 9 Gene Leendert H.J. Looijenga,1 Remko Hersmus,1 Ad J.M. Gillis,1 Rolph Pfundt,4 Hans J. Stoop,1 Ruud J.H.L.M. van Gurp,1 Joris Veltman,1 H. Berna Beverloo,2 Ellen van Drunen,2 Ad Geurts van Kessel,4 Renee Reijo Pera,5 Dominik T. Schneider,6 Brenda Summersgill,7 Janet Shipley,7 Alan McIntyre,7 Peter van der Spek,3 Eric Schoenmakers,4 and J. Wolter Oosterhuis1 1Department of Pathology, Josephine Nefkens Institute; Departments of 2Clinical Genetics and 3Bioinformatics, Erasmus Medical Center/ University Medical Center, Rotterdam, the Netherlands; 4Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands; 5Howard Hughes Medical Institute, Whitehead Institute and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts; 6Clinic of Paediatric Oncology, Haematology and Immunology, Heinrich-Heine University, Du¨sseldorf, Germany; 7Molecular Cytogenetics, Section of Molecular Carcinogenesis, The Institute of Cancer Research, Sutton, Surrey, United Kingdom Abstract histochemistry, DMRT1 (a male-specific transcriptional regulator) was identified as a likely candidate gene for Spermatocytic seminomas are solid tumors found solely in the involvement in the development of spermatocytic seminomas. testis of predominantly elderly individuals. We investigated these tumors using a genome-wide analysis for structural and (Cancer Res 2006; 66(1): 290-302) numerical chromosomal changes through conventional kar- yotyping, spectral karyotyping, and array comparative Introduction genomic hybridization using a 32 K genomic tiling-path Spermatocytic seminomas are benign testicular tumors that resolution BAC platform (confirmed by in situ hybridization).
    [Show full text]
  • Characterization of X-Linked SNP Genotypic Variation in Globally Distributed Human Populations Genome Biology 2010, 11:R10
    Casto et al. Genome Biology 2010, 11:R10 http://genomebiology.com/2010/11/1/R10 RESEARCH Open Access CharacterizationResearch of X-Linked SNP genotypic variation in globally distributed human populations Amanda M Casto*1, Jun Z Li2, Devin Absher3, Richard Myers3, Sohini Ramachandran4 and Marcus W Feldman5 HumanAnhumanulation analysis structurepopulationsX-linked of X-linked variationand provides de geneticmographic insights variation patterns. into in pop- Abstract Background: The transmission pattern of the human X chromosome reduces its population size relative to the autosomes, subjects it to disproportionate influence by female demography, and leaves X-linked mutations exposed to selection in males. As a result, the analysis of X-linked genomic variation can provide insights into the influence of demography and selection on the human genome. Here we characterize the genomic variation represented by 16,297 X-linked SNPs genotyped in the CEPH human genome diversity project samples. Results: We found that X chromosomes tend to be more differentiated between human populations than autosomes, with several notable exceptions. Comparisons between genetically distant populations also showed an excess of X- linked SNPs with large allele frequency differences. Combining information about these SNPs with results from tests designed to detect selective sweeps, we identified two regions that were clear outliers from the rest of the X chromosome for haplotype structure and allele frequency distribution. We were also able to more precisely define the geographical extent of some previously described X-linked selective sweeps. Conclusions: The relationship between male and female demographic histories is likely to be complex as evidence supporting different conclusions can be found in the same dataset.
    [Show full text]
  • Variation in Protein Coding Genes Identifies Information Flow
    bioRxiv preprint doi: https://doi.org/10.1101/679456; this version posted June 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Animal complexity and information flow 1 1 2 3 4 5 Variation in protein coding genes identifies information flow as a contributor to 6 animal complexity 7 8 Jack Dean, Daniela Lopes Cardoso and Colin Sharpe* 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Institute of Biological and Biomedical Sciences 25 School of Biological Science 26 University of Portsmouth, 27 Portsmouth, UK 28 PO16 7YH 29 30 * Author for correspondence 31 [email protected] 32 33 Orcid numbers: 34 DLC: 0000-0003-2683-1745 35 CS: 0000-0002-5022-0840 36 37 38 39 40 41 42 43 44 45 46 47 48 49 Abstract bioRxiv preprint doi: https://doi.org/10.1101/679456; this version posted June 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Animal complexity and information flow 2 1 Across the metazoans there is a trend towards greater organismal complexity. How 2 complexity is generated, however, is uncertain. Since C.elegans and humans have 3 approximately the same number of genes, the explanation will depend on how genes are 4 used, rather than their absolute number.
    [Show full text]
  • MAGEA4 (NM 001011548) Human Untagged Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for SC301576 MAGEA4 (NM_001011548) Human Untagged Clone Product data: Product Type: Expression Plasmids Product Name: MAGEA4 (NM_001011548) Human Untagged Clone Tag: Tag Free Symbol: MAGEA4 Synonyms: CT1.4; MAGE-41; MAGE-X2; MAGE4; MAGE4A; MAGE4B Vector: pCMV6 series Fully Sequenced ORF: >NCBI ORF sequence for NM_001011548, the custom clone sequence may differ by one or more nucleotides ATGTCTTCTGAGCAGAAGAGTCAGCACTGCAAGCCTGAGGAAGGCGTTGAGGCCCAAGAA GAGGCCCTGGGCCTGGTGGGTGCACAGGCTCCTACTACTGAGGAGCAGGAGGCTGCTGTC TCCTCCTCCTCTCCTCTGGTCCCTGGCACCCTGGAGGAAGTGCCTGCTGCTGAGTCAGCA GGTCCTCCCCAGAGTCCTCAGGGAGCCTCTGCCTTACCCACTACCATCAGCTTCACTTGC TGGAGGCAACCCAATGAGGGTTCCAGCAGCCAAGAAGAGGAGGGGCCAAGCACCTCGCCT GACGCAGAGTCCTTGTTCCGAGAAGCACTCAGTAACAAGGTGGATGAGTTGGCTCATTTT CTGCTCCGCAAGTATCGAGCCAAGGAGCTGGTCACAAAGGCAGAAATGCTGGAGAGAGTC ATCAAAAATTACAAGCGCTGCTTTCCTGTGATCTTCGGCAAAGCCTCCGAGTCCCTGAAG ATGATCTTTGGCATTGACGTGAAGGAAGTGGACCCCGCCAGCAACACCTACACCCTTGTC ACCTGCCTGGGCCTTTCCTATGATGGCCTGCTGGGTAATAATCAGATCTTTCCCAAGACA GGCCTTCTGATAATCGTCCTGGGCACAATTGCAATGGAGGGCGACAGCGCCTCTGAGGAG GAAATCTGGGAGGAGCTGGGTGTGATGGGGGTGTATGATGGGAGGGAGCACACTGTCTAT GGGGAGCCCAGGAAACTGCTCACCCAAGATTGGGTGCAGGAAAACTACCTGGAGTACCGG CAGGTACCCGGCAGTAATCCTGCGCGCTATGAGTTCCTGTGGGGTCCAAGGGCTCTGGCT GAAACCAGCTATGTGAAAGTCCTGGAGCATGTGGTCAGGGTCAATGCAAGAGTTCGCATT GCCTACCCATCCCTGCGTGAAGCAGCTTTGTTAGAGGAGGAAGAGGGAGTCTGA
    [Show full text]